Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
NCT04771520Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of avapritinib in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2021; status: recruiting.
02
Drugs
avapritinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04771520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771520.